These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 38455648)

  • 21. Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
    Zhang MZ; Wang S; Yang S; Yang H; Fan X; Takahashi T; Harris RC
    Am J Physiol Renal Physiol; 2012 Feb; 302(4):F433-8. PubMed ID: 22114203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Narrative review of the effects of antidiabetic drugs on albuminuria.
    Yaribeygi H; Atkin SL; Katsiki N; Sahebkar A
    J Cell Physiol; 2019 May; 234(5):5786-5797. PubMed ID: 30367464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive interaction of mangiferin with selected oral hypoglycemic drugs: a therapeutic strategy to alleviate diabetic nephropathy in experimental rats.
    Sekar V; Mani S; Malarvizhi R; Barathidasan R; Vasanthi HR
    Mol Biol Rep; 2020 Jun; 47(6):4465-4475. PubMed ID: 32451927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors?
    Giles TD; Sander GE
    Am J Geriatr Cardiol; 2002; 11(1):62-5. PubMed ID: 11773721
    [No Abstract]   [Full Text] [Related]  

  • 31. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
    Muskiet MH; Smits MM; Morsink LM; Diamant M
    Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.
    Abdel-Rahman EM; Saadulla L; Reeves WB; Awad AS
    J Gen Intern Med; 2012 Apr; 27(4):458-68. PubMed ID: 22005942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saccharomyces boulardii exerts renoprotection by modulating oxidative stress, renin angiotensin system and uropathogenic microbiota in a murine model of diabetes.
    Abreu ICME; Albuquerque RCMF; Brandão ABP; Barssotti L; de Souza LB; Ferreira FG; Oliveira LCG; Yokota R; Sparvoli LG; Dias DDS; Salgado MAC; Taddei C; De Angelis K; Casarini DE; Cunha TS
    Life Sci; 2022 Jul; 301():120616. PubMed ID: 35533758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diabetic nephropathy: the role of blood pressure and extra-cellular volume in its pathogenesis and treatment].
    Braam B; de Koning EJ; Mees EJ
    Ned Tijdschr Geneeskd; 2004 Jan; 148(5):212-7. PubMed ID: 14983575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D and diabetic nephropathy.
    Li YC
    Curr Diab Rep; 2008 Dec; 8(6):464-9. PubMed ID: 18990303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative stress in diabetic nephropathy.
    Kashihara N; Haruna Y; Kondeti VK; Kanwar YS
    Curr Med Chem; 2010; 17(34):4256-69. PubMed ID: 20939814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.